4//SEC Filing
Arno Therapeutics, Inc 4
Accession 0000914190-16-000519
CIK 0001195116operating
Filed
Jan 13, 7:00 PM ET
Accepted
Jan 14, 5:20 PM ET
Size
17.6 KB
Accession
0000914190-16-000519
Insider Transaction Report
Form 4
Zukiwski Alexander A
VP & Chief Medical Officer
Transactions
- Purchase
Common Stock
2016-01-12$0.35/sh+144,806$50,682→ 261,832 total
Holdings
- 109,375
Stock Option (right to buy)
Exercise: $2.40Exp: 2021-06-22→ Common Stock (109,375 underlying) - 36,562
Stock Option (right to buy)
Exercise: $2.40Exp: 2023-01-14→ Common Stock (36,562 underlying) - 12,187
Stock Option (right to buy)
Exercise: $2.40Exp: 2023-01-14→ Common Stock (12,187 underlying) - 55,736
Stock Option (right to buy)
Exercise: $2.40Exp: 2021-06-22→ Common Stock (55,736 underlying) - 316,389
Stock Option (right to buy)
Exercise: $2.40Exp: 2023-11-04→ Common Stock (316,389 underlying) - 183,822
2012 Series A Warrants (right to buy)
Exercise: $1.36From: 2012-11-26Exp: 2017-11-26→ Common Stock (183,822 underlying) - 711,301
Stock Option (right to buy)
Exercise: $2.90Exp: 2024-01-24→ Common Stock (711,301 underlying) - 77,880
2013 Series D Warrants (right to buy)
Exercise: $2.14From: 2013-10-29Exp: 2018-10-29→ Common Stock (77,880 underlying)
Footnotes (7)
- [F1]On January 12, 2016, the Reporting Person was issued 144,806 shares upon the automatic conversion of $50,682.19 of principal and accrued interest under a 6% unsecured convertible promissory note previously issued to the Reporting Person by the Issuer on October 21, 2015.
- [F2]Currently exercisable.
- [F3]On 6/22/2011, the Reporting Person was granted an option to purchase up to 109,375 shares of common stock of the Issuer. Up to 1/3 of the shares subject to the option may vest annually (or a pro rata portion thereof for a period of less than a full year) based on the achievement of cerain performance milestones as determined by the Board of Directors (the 'Board') of the Issuer. On 1/17/2012, the Board determined that options for the prorated period ending 12/31/2011 would vest in the maximum potential amount of 19,278 shares. On 1/14/2013, the Board determined that options for the period ending 12/31/2012 would vest in the maximum potential amount of 36,458 shares.
- [F4]Vests in equal 36-monthly installments commencing 12/4/13.
- [F5]On 1/14/13, the Reporting Person was granted an option to purchase up to 36,562 shares of common stock of the Issuer. 1/3 of the shares subject to the option were immediately vested and up to 1/2 of the remaining shares subject to the option may vest annually, based on the achievement of certain performance milestones as determined by the Board.
- [F6]Vests 25% on first anniversary date and thereafter will vest in 24 equal monthly installments.
- [F7]As a result of the Issuer's 1/12/16 private placement of common stock at $0.35/share, the exercise price and number of shares subject to the 2012 Series A Warrants and 2013 Series D Warrants were automatically adjusted to the exercise price and shares reflected, pursuant to anti-dilution adjustment provisions.
Documents
Issuer
Arno Therapeutics, Inc
CIK 0001195116
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001195116
Filing Metadata
- Form type
- 4
- Filed
- Jan 13, 7:00 PM ET
- Accepted
- Jan 14, 5:20 PM ET
- Size
- 17.6 KB